Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.62 USD

1.62
1,533,635

+0.08 (5.19%)

Updated May 3, 2024 04:00 PM ET

After-Market: $1.62 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?

Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.

Accuray's (ARAY) CyberKnife System Gets Shonin Approval

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray

Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray

Urmimala Biswas headshot

3 Top Medical Instruments Stocks to Counter Industry Headwinds

The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most. Yet, demand for base business is on the decline with the new COVID variant disrupting the trend.

Accuray (ARAY) Down 15.3% Since Last Earnings Report: Can It Rebound?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Earnings Estimates Rising for Accuray (ARAY): Will It Gain?

Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Here's What Could Help Accuray (ARAY) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down

Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.

Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment

Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.

Accuray's (ARAY) Radiotherapy Technologies Adopted by Unicancer

Accuray's (ARAY) proprietary radiotherapy technologies get selected by Unicancer, which is the largest network of comprehensive cancer centers in Europe.

Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment

Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.

Why Is Accuray (ARAY) Down 3.4% Since Last Earnings Report?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.

Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of 0.00% and 9.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray's (ARAY) CyberKnife Gets Support From RayStation TPS

Accuray (ARAY) introduces RayStation treatment planning support for CyberKnife Radiotherapy System and other radiation therapy devices.

Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT

Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.

Accuray (ARAY) Down 13.1% Since Last Earnings Report: Can It Rebound?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

New Strong Sell Stocks for April 30th

ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.